(Ophthalmic Res[TA])
2,837 results
  • Ocular Manifestations and Management of Graft-versus-Host Disease: A Comprehensive Review. [Review]
    Ophthalmic Res. 2026; 69(1):301-315.Chatterjee S, Gupta J, … Sharma NOR
  • CONCLUSIONS: While the ocular surface is primarily affected, oGVHD can also impact other eye components, leading to debilitating symptoms. The diagnosis of oGVHD poses significant challenges due to its relapsing and remitting nature, complicating effective treatment strategies. Prompt identification of ocular manifestations is essential, as early intervention can prevent vision-threatening complications and improve patient outcomes. As research continues to evolve, understanding the underlying mechanisms and exploring innovative therapeutic options will be crucial in managing this complex condition effectively.This review highlights the importance of heightened awareness among healthcare providers regarding the ocular signs of GVHD, advocating for timely diagnosis and personalised treatment approaches.
  • Patient and Neighborhood Factors Influencing Participation in a Personalized Glaucoma Coaching Program. [Journal Article]
    Ophthalmic Res. 2026; 69(1):276-285.Lee S, Hicks PM, … Newman-Casey PAOR
  • CONCLUSIONS: Among SEE pilot program participants, acceptability barriers and awareness facilitators were the most frequently cited. There were ADI differences for barriers and facilitators. Neighborhood factors should be considered when implementing glaucoma coaching programs, as program interaction varies by these characteristics. The SEE pilot program facilitated glaucoma medication adherence through educational resources and adherence monitoring tools.
  • Erratum. [Published Erratum]
    Ophthalmic Res. 2026; 69(1):236.OR
  • In the article by Feng et al. entitled "Postoperative Outcomes and Prognostic Factors of High Myopia-Epiretinal Membrane Associated with Retinoschisis after Vitrectomy" [Ophthalmic Res. 2025;68:275-284; https://doi.org/10.1159/000544928], there is an error where the funding number was incorrectly listed as 8240040319. The correct National Natural Science Foundation of China (NSFC) Grant No. shoul…
  • Construction and Applications of Knowledge Graphs in Ophthalmology. [Review]
    Ophthalmic Res. 2026; 69(1):263-275.Chen S, Chen HOR
  • CONCLUSIONS: This paper reviews the methodologies for constructing medical KGs and highlights their applications in ophthalmology, with particular emphasis on the integration of ophthalmic KGs with medical imaging and large language models. Furthermore, it discusses existing challenges - ranging from privacy and regulatory constraints to high construction and maintenance costs, limited fusion of imaging and multimodal data, insufficient coverage of rare eye diseases and insufficient application in education and basic research - aiming to provide insights that promote deeper research and clinical translation of ophthalmology KGs.The integration of KGs with multimodal technologies represents a research frontier in the transformation of ophthalmic clinical practice, enabling more structured and precise diagnostic reasoning. Future research should focus on the construction of domain-specific KGs for rare ocular diseases and spearhead the development of multimodal knowledge frameworks to fill existing knowledge gaps, thereby ultimately enhancing both patient clinical outcomes and medical education.
  • The Link between Obstructive Sleep Apnea and Dry Eye Disease: Pathophysiology and Current Updates. [Review]
    Ophthalmic Res. 2026; 69(1):252-262.Pai HL, Pan TC, Tsao CHOR
  • CONCLUSIONS: Continuous positive airway pressure (CPAP) therapy is the standard treatment for OSA patients with both beneficial and detrimental effects. It alleviates inflammation and hypoxia while potentially exacerbating DED due to airflow leakage or retrograde air movement. Mechanical factors such as face-down sleeping positions and habitual eye rubbing enhance the risk of meibomian gland dysfunction in OSA patients. This review highlights the multifactorial etiology of OSA-related DED, highlighting the roles of systemic and ocular inflammation, lipid metabolism dysfunction, and mechanical stress.We also emphasize the need for interdisciplinary management, combining sleep medicine and ophthalmology, to optimize outcomes for OSA patients with ocular surface disorders. Future research into targeted therapies, such as modulation of the Hif/NF-κB pathways and innovative CPAP device designs, holds promise for mitigating OSA-induced ocular complications.
  • Stem Cell-Based Interventions for Retinal Ganglion Cell Protection and Regeneration in Glaucoma: A Review of Current Evidence and Future Directions. [Review]
    Ophthalmic Res. 2026; 69(1):237-251.Chen TY, Meng M, … Sun XOR
  • CONCLUSIONS: Stem cell interventions have the unique potential to assist with the preservation and restoration of dysfunctional RGCs via direct cellular replacement, differential neuroprotection, and stimulation of endogenous repair mechanisms. The focus of this review is on the most contemporary innovations which utilize stem cells to preserve and regenerate RGCs, which are vitally important for sight. The review addresses some of the newer cell source and cell prep technologies, particularly those using disorganized retinal microenvironment cell preps. Retinal microenvironment cell preps have resulted in some novel microenvironment cells designed to sequester stem cell grafts, to improve stem cell microenvironment cell preps, and to augment microenvironment cell preps. Some of the major challenges are reconstructing and integrating the lost retino-tectal and retino-collateral synapses in the visual pathway and the axonal outgrowth to and targeting appropriate central visual synaptic areas.Some major challenges are safety, RGC immunochemistry and cell type diversity, and scalable cell prep technologies. This review encapsulates how stem cell biology, along with other technologies like gene editing and tissue engineering, is forming the basis for developing first-of-its-kind regenerative therapies to restore vision in glaucoma patients, based on recent preclinical studies and ongoing early-phase clinical trials.